secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMAC Holdings, Inc. (BACK)
CIK:        0001729944
Form:       8-K
Filed at:   2023-05-26T23:59:59+00:00
Accession:  0001493152-23-019327
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IMAC Holdings to acquire Theralink in reverse merger; Theralink shareholders to own 85%
--------------------------------------------------------------------------------

- Stock-for-stock reverse merger: Theralink survives as wholly owned subsidiary of IMAC (BACK).
- Theralink stakeholders expected to own ~85% of combined company; pre-merger IMAC holders ~15%.
- Merger expected to close late Q3 or early Q4 2023, subject to shareholder and regulatory approvals.
- All current IMAC directors except one to resign at close; Theralink directors appointed, Jeffrey Busch as Chairman.
- Combined company to focus on Theralink's proteomics cancer testing platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1729944/000149315223019327/0001493152-23-019327-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1729944/000149315223019327/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-019327

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer